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Prostatic urethraAbstract Background: Foley’s catheter indwelling gives temporary relief for lower urinary tract
obstruction, especially in case of severely symptomatizing benign prostatic hyperplasia (BPH). Sev-
eral complications of long-term or frequent catheter indwelling have been reported in catheter
dependent patients, speciﬁcally to those who are unﬁt for operative intervention.
Objectives: Our aim was to ﬁnd a safe, non-invasive relief from symptom severity, as well as, inca-
pacitating complications of Foley’s catheter in catheter-dependent patients.
Methods: A total of 107 catheter-dependent men, or who had frequent Foley’s catheter indwelling
in case of BPH, participated in the present study. Preliminary estimation of the post-micturition
residual urine was obtained. Ultrasound elastography was used to assess the transurethral balloon
pressure of the double balloon silicon-coated catheter, adjudicated by ureteromat, and maintained
in situ for 6 days in all patients. Basic follow up once-a-month has been performed up to 6 months.
Results: Effectual urethral patency was noted in 89.7% patients at the end of the third month. The
procedure was repeated for 11 patients shortly after 3 months, for 7 patients after 4 months and for
28 patients after 5 months, with no reported prostatic urethral injury. No stricture recurrence was
noted in 61 patients up to 6 months.
1286 Elwagdy S. et al.Conclusions: Preliminary results indicate that prostatic urethral balloon dilation in BPH catheter-
dependent patients is inexpensive, safe, and would be a potentially effective option in maintaining
the prostatic urethral patency. Elastographic justiﬁcation of the transurethral balloon has proved to
be helpful.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.1. Introduction
Benign prostate hypertrophy (BPH) is, without doubt, the
most common cause of urinary outﬂow obstruction. Almost
more than 80 years ago, Foley’s catheter has been in use in
conditions that makes it difﬁcult to urinate, such as prostate
hypertrophy or stricture of the urethra (1,2).
There are several articles which reported complications
attributable to frequent or long-term usage of the Foley’s
catheter such as the introduction of infection into the blad-
der, or from intimate contact of the mucosal layer of the uri-
nary bladder to the distended intra-vesical balloon and the
catheter tip, which alert patients and are considered as predis-
posing factors for secondary catheter cystitis. Also, frequent
insertion of Foley’s catheters in patients at high risk for long
periods would injure the urethra due to manifold insertions
that may lead to ﬁstula or false passage (3–5). Moreover,
there are some articles which reported urinary bladder perfo-
rations (6–8).
Over the years, transurethral resection of the prostate
(TURP) was the preferred gold standard treatment for symp-
tomatic prostatic obstruction (3). More recently, laser abla-
tion, or variants of direct therapeutic injection into the gland
were reported (9–13). These techniques often successfully
achieve at least a temporary increase in the caliber of the pros-
tatic urethra and relief from symptoms severity.
Nevertheless, few trials of transurethral balloon dilation
have been reported in patients with BPH and those unﬁt for
operation, started by Reddy (14) and Wasserman (15). The
procedure has been updated by Takeda et al. (16) by means
of a double Malecot type polyurethane intraurethral catheter.
Also, in 1993, Hernandez-Graulau (17), mentioned that trans-
urethral balloon dilation (TUBD) of the prostatic urethra is
simple and safe, represents a nonoperative alternative treat-
ment for symptomatic BPH. He performed his study via ure-
thra-cystoscopy; inserting a guidewire and three balloon
catheters under ﬂuoroscopic guide.
However, and in respect to the previous trials of TUBD, no
standardization of the transurethral balloon pressure was
reported.
As well and until recently we were not able to visualize via
the available diagnostic tools the real BPH pathology as
described by McNeal (18), who conﬁrmed that BPH is not a
diffuse involvement of the prostate gland but develops as a
nodular growth in the central gland, more frequently the
peri-urethral transitional zone and to a lesser extent involves
the central zone.
Recently, we could visualize radiologically the BPH nod-
ules as described by McNeal. In the year 2008 we investigated
by means of transrectal three-dimension ultrasound (3D US)
extended imaging (3D XI) technology (19) the BPH nodularhypertrophy and their effect on the prostatic urethra. Our
report contributed the symptoms-severity of BPH, aspires by
means of the balance and the type of extra-axial BPH nodular
effect on the prostate urethra.
Elastography, on the other hand, is an important assisting
tool, considered as an upgrade of the conventional ultrasound
transducers to differentiate pathologies by means of measuring
the degree of soft tissue stiffness either by the elastographic
reﬂected color map; green for ﬂuid, blue for less hard probably
benign soft-tissue and red for probably malignant tissues, or
more recently by measuring the elastographic index of tissues.
This technology is usually referred to as virtual palpation (20,21).
Our objective is to increase the caliber and/or rebalance the
BPH nodular weight of the prostatic urethra by means of
TUBD, guided by an elastographic color-map to adjust the
trans-urethral balloon pressure in patients unﬁt for operative
interventions and on frequent or long-term Foley’s catheter
indwelling. In addition, the technique aimed to minimize the
possibility of secondary infection and prevent trickling of urine
wetting the patient’s clothes.2. Methods
The protocol of the present study was approved by the local
ethics committee. Three-dimensional transrectal ultrasound
(3D-TRUS) assessment of the pattern of BPH, with volumetric
assessment of post-micturition residual urine (PM) and any
bladder pathology was performed on each patient.
2.1. Patient selection
The procedure was practiced on men who have severe LUTS
due to BPH, and were unﬁt for operative intervention. Any
patient with PM residual urine less than 100 mL or having
bladder pathology has been excluded from our study.
107 patients signed a written informed consent for our pro-
cedure from May 2010 to December 2013; their ages ranged
from 67 to 83 years (mean 68.3 years), divided into 3 groups
according to the PM volumes: >100 mL, >200 mL and
>300 mL, according to Beekman et al. (22), Managadze
et al. (23), and Al0-Shukri and Amdii (24).
2.2. Equipment
(1) Local sterilization by betadine solution. (2) Flexible three
way double balloon Silicon-coated catheter (20 Ch.), (Yangz-
hou, Jiangsu, China). This type of catheter is entirely Sili-
con-coated, has a soft rounded closed tip and safe
symmetrical distal (trans-urethral) balloon inﬂation up to
30 mL, proximal (trans-vesical) balloon of 50 mL capacity
Transurethral balloon dilation of prostatic urethra 1287and catheter draining-way plug. (3) Lubricant containing 2%
lidocaine. (4) Syringe for balloon-water inﬂation. (5) Sterile
water for irrigation and assessment of ﬂow patency. (6) Ultra-
sound machine (Samsung-Medison, Accuvix V20, Seoul,
South Korea) having the capabilities of ultrafast 3D US and
elastography, and transrectal probes (5–9 MHz) for 3-D
volume acquisition and elastography. (7) Ureteromat.
2.3. Procedure
Patients were placed in the lithotomy position. The catheter tip
was lubricated and then advanced under local anesthesia and
real-time transrectal ultrasound direct vision, having in consid-
eration the anatomy of the prostate urethra, which anatomi-
cally traverses the prostate gland from the bladder neck to
the apex and having a curve of 35 degrees anterocaudally.
The transurethral balloon is then placed opposite the anatom-
ical location of the transitional and central prostatic zones,
almost within the proximal 1/2 of the prostatic urethra; closer
to the bladder neck.
The transurethral balloon is then slowly inﬂated gradually
with water, controlled by transrectal ultrasound elastographic
color map and ureteromat. We have used ureteromat to assess
the elastographic transurethral balloon suitable pressure. In
addition, and according to the ethical standards, the patient’s
sense of pain was a sign to stop inﬂation instantly, to avoid
urethral injury. However, we must highlight the importance
of maintaining light pressure on the prostate gland by the
probe for 5 seconds during US elastography for reliable elasto-
graphic assessment of the pressure within the balloon. The
intra-vesical balloon is then sufﬁciently inﬂated. The external
portion of the catheter was color-marked and plastered for sta-
bility (Fig. 1). After proper irrigation, plugging the catheter
draining-way was done, left until the patient feels desire for
emptying, removed and then re-plugged. The catheter was
ﬁxed and left in situ for 6 days. The patient is discharged from




Fig. 1 Schematic illustration for the double balloon catheter insert
guided by elastography and ureteromat, and then the intra-vesical ballofollow up once-a-month was performed up to 6 months for
each patient.
3. Results
We could assess the proper elasticity of the trans-urethral
balloon to avoid prostatic urethral injury. The elasticity green-
color of the transurethral balloon was interpreted to be equiva-
lent to 10 ± 0.5 atmospheric pressure unit (ATM) and almost
about 15–20 mL of water, which indicates a stable proper inﬂa-
tion (Fig. 2). It is worthy to mention that the red color elasticity
indicates hardness of the balloon and means a strong compres-
sion, which may alert the patient and make him reluctant.
There was no technical procedure-related complication.
Nevertheless, 37 patients (34.6%) suffered from discomfort
during catheter insertion, 3 (2.8%) noticed minor bleeding
shortly after catheter insertion, and 4 (3.7%) urinary tract
infections after one week.
Effectual urethral patency was noted in 89.7% patients at
the end of the third month, with improvement in voiding after
the transurethral balloon dilation (TUBD), with diminution of
the PM< 100 mL, continued in 61 patients (57%) up to
6 months in the second routine follow up. The procedure
was repeated in 11 patients (10.3%) after 3 months, 7 patients
(6.5%) after 4 months, and 28 patients (26.2%) after 5 months.
The decline in symptomswas strongly signiﬁcant for patients
in groups 1 and 2 (p 6 0.05). However, the magnitude of drop in
symptoms after TUBDwas signiﬁcantly greater in group 1 than
in groups 2 and 3. This necessitated a repeat of TUBD for 46
patients (43%) in groups 2 and 3, although not strongly at a
statistically signiﬁcant level (p 6 0.07) in group 3. The improve-
ment attained in group 1was consistently in the less PM residual
urine range (Table 1). Generally, sustainable statistically signif-
icant improvements in symptoms were reported by all patients
with balanced BPH rather than those with unbalanced BPH
(Figs. 3 and 4). However, patients with unbalanced BPH
returned willingly for the second TUBD.ter 
Foley’s catheter 






           Rubber plug. 
ion. The transurethral balloon is inﬂated ﬁrst at 10 ± 0.5 ATM
on is inﬂated. The draining way is lastly blocked by a rubber plug.
Fig. 2 Estimation of the trans-urethral balloon pressure by elastography. The green color (asterisk) justiﬁes 10 ± 0.5 ATM adjudicated
by ureteromat. The surrounded blue color is of the senile prostatic tissue.
Table 1 BPH patterns, transurethral balloon dilation (TUBD) and follow up of 107 men with LUTs due to BPH.




Follow up (Months) PM (average) in mL PV
1–3 4–6
Group 1 47 Balanced 113 ± 0.3 6 42 ± 0.3 49 ± 0.7 <.01
5 Unbalanced 158 + 0.6 6 51 ± 0.5 66 ± 0.3 <.03
Group 2 9 Balanced 219 ± 0.3 6 64 ± 0.5 73 ± 0.2 <.01
28 Unbalanced 229 ± 0.8 6 89 ± 0.7 +++113 ± 0.9 <.05
Group 3 7 Balanced 303 ± 0.9 6 92 ± 0.4 ++118 ± 0.5 =.05
11 Unbalanced 327 ± 0.4 6 +108 ± 0.6 +132 ± 0.5 <.07
BPH: benign prostatic hyperplasia.
PM: post-micturition residual urine.
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Urethral dilation is not historically a common method used to
treat patients with BPH. Our preliminary diagnostic criteria in
the present study depend mainly on the degree and pattern of
BPH nodular balance and the consequent compression effect
upon the prostatic urethra, manifested by unadorned micturi-
tion symptoms and being unﬁt for operative intervention
(16,19). Conversely, in the previous reports (9,11) of patients
submitted to TURP or laser ablation, the selection criteria
and outcome, were mainly inﬂuenced by the size of the pros-
tate gland rather than the BPH nodular balance-effect. Several
complications were reported in the previous TUBD trials(14–17), mostly due to nonexistence of measuring the transure-
thral balloon pressure or stiffness to leave in situ for several
days without injury of the prostatic urethra.
The idea of our method is to induce a mechanical compres-
sion upon the BPH nodules, fair enough for BPH nodular
atrophy, so as to rebalance the para-urethral nodular weight
and regain the prostatic urethra normal anatomy and patency.
Using elastography in the present study is to assess the
degree of elasticity or pressure-stiffness of the transurethral
balloon captured within the prostatic urethra. Thus, elasticity
herein will reﬂect the pressure-effect of ﬂuid within the balloon
enclosed by the prostate upon the peri-urethral prostatic tis-
sues. Leaving the transurethral balloon inﬂated for 6 days
PG
UB 
Fig. 3 Transrectal 3D XI ultrasound at stage one inﬂation of the
transurethral balloon (asterisk) opposite the hypertrophied por-
tion of the prostate gland (PG). UB: Urinary bladder.
Fig. 4 3D XI ultrasound of inﬂated transurethral balloon
opposite the hypertrophied portion of the central gland (FC).
PROST: prostate gland.
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atrophy of the extra-axial BPH nodules. This comes after sev-
eral previous sporadic trials in agreement with some individu-
als, nonetheless, which were not statistically reported and
would be considered as a preliminary experience before start-
ing effectively the present study. On the other hand, we
depended upon the elasticity color-scale for instant assessment
rather than measuring the elasticity indices, which consume
more time during our procedure of usually busy hands.
On the other hand, we substitute the draining bag by a rub-
ber plug, to close the catheter outlet, until the patient feels a
desire for emptying. This was of value to make the urinary
bladder averagely ﬁlled with urine most of time, so as to
eliminate the factor of permanent balloon and the catheter ter-
minal contact with the bladder mucosa, which was reported asa predisposing factor for secondary catheter cystitis and colo-
nization (3–5). In addition; trickling of urine along the catheter
will be constantly prevented.
The reported technical procedure-related minor complica-
tion in our series, chanced shortly after catheter insertion, can
be considered negligible if compared with the complications of
the other treatment strategies as mentioned by Shrivastava
and Vipin (11) in their review evaluation of various treatment
options for BPH.
Because we had prospectively assigned most patients into
categories meeting our selective criteria, our results showed
that the nodular balance reﬂects different degrees of obstruc-
tion. On the other hand, the difference in symptomatic
response to TUBD was more signiﬁcant in each group with
balanced nodular hyperplasia than in unbalanced. This means
that patients in the three groups with balanced nodular
hyperplasia beneﬁted to a greater extent than did those with
unbalanced obstruction (58.9%).
However, the recurrence rate in the present study seems to
be higher than the results of Arash et al. (10), Shrivastava and
Vipin (11), Samuel et al. (12) and Li et al. (13), who performed
transurethral prostatectomy for their patients with similar
symptoms severity. This may be due to harder stromal nodules
(19), not to be easily ﬂared under the balloon pressure.
As far as we are aware, this is the ﬁrst study, which has pro-
vided necessary information to help radiologists and urologists
to critically evaluate the role of our technique in the treatment
of lower urinary tract symptoms (LUTS) due to BPH.
Our study had some limitations. First, we evaluated only a
limited group of patients. Second, this is a non-randomized
prospective case-controlled study, where the decision to per-
form TUBD was made at the time of each examination. Thus,
a possible selection bias inﬂuencing the results could be consid-
ered. Third, our study required training in ultrasound elastog-
raphy and the ultrasound 3D XI methods. The risk of urethral
injury or rupture during balloon dilation did not happen in our
study, because dilation was effectually controlled by elastogra-
phy and ureteromat, and each balloon was not inﬂated
abruptly. However, further studies are needed to assess long-
term efﬁcacy.
This study also signiﬁes the value of collaboration between
urology and radiology in applying techniques outside the usual
discipline of each specialty. The medical community would be
better if they extend the limits of collaboration.
In conclusion out preliminary results indicate that prostatic
urethral balloon dilation can be considered as an adjunctive
option to medical treatment in reducing prostatic urethral
compromise due to BPH and maintaining urethral patency
for fair period. The color-scale available on the ultrasound
elastography conjoined with 3D-TRUS images has proved to
be valuable in estimating the balloon pressure, lest of urethral
injury.Conﬂict of interest
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